Anovel serum metabolomics-based diagnostic approach to pancreatic cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 4, 2013, Pages 571-579

  Kobayashi, Takashi ^a   Nishiumi, Shin ^a   Ikeda, Atsuki ^a   Yoshie, Tomoo ^a   Sakai, Aya ^a   Matsubara, Atsuki ^a   Izumi, Yoshihiro ^a   Tsumura, Hidetaka ^e   Tsuda, Masahiro ^e   Nishisaki, Hogara ^e   Hayashi, Nobuhide ^d   Kawano, Seiji ^d   Fujiwara, Yutaka ^b   Minami, Hironobu ^b   Takenawa, Tadaomi ^a   Azuma, Takeshi ^a   Yoshida, Masaru ^a,c  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Medical Oncology/Hematology   (United States)

^c Metabolomics Research Department of Internal Medicine   (Japan)

^d KOBE UNIVERSITY HOSPITAL   (Japan)

^e HYOGO CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ALANINE; ARABINITOL; ARABINOSE; ASPARAGINE; ASPARTIC ACID; CREATININE; ETHANOLAMINE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; GLYCOLIC ACID; HISTIDINE; HYDROXYBUTYRIC ACID; INOSITOL; LACTIC ACID; LAURIC ACID; METHIONINE; NONANOIC ACID; OXALOACETIC ACID; PHENYLALANINE; PHOSPHATE; PROLINE; PYROGALLOL; PYRUVIC ACID; THREONINE; TUMOR MARKER; TYROSINE; VALINE; XYLITOL;

AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; MASS FRAGMENTOGRAPHY; METABOLOMICS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; ACINAR CELL CARCINOMA; ADULT; BLOOD; CANCER STAGING; CASE CONTROL STUDY; COLLOID CARCINOMA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PANCREAS CARCINOMA; PANCREAS TUMOR; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ACINAR CELL; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; METABOLOMICS; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84876527313     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1033     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10:88-95.
3. Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 2005;128:1626-41. (Pubitemid 40692556)
4. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 2012;3: 105-19.
5. Rehani MM, Berry M. Radiation doses in computed tomography. The increasing doses of radiation need to be controlled. BMJ (Clinical research ed) 2000;320:593-4. (Pubitemid 30175818)
6. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007;357:2277-84. (Pubitemid 350190758)
7. Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012;380:499-505.
8. Gonda TA, Saif MW. Early detection and screening of pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP 2011;12:83-5.
9. Eguia V, Gonda TA, SaifMW.Early detection of pancreatic cancer. JOP 2012;13:131-4.
10. Fry LC, Monkemuller K, Malfertheiner P. Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg 2008;393:883-90.
11. Kawa S, Tokoo M, Hasebe O, Hayashi K, Imai H, Oguchi H, et al. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer 1994;70:481-6. (Pubitemid 24268551)
12. Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 2004;49:1149-55. (Pubitemid 39178081)
13. Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin Can Res 2009;15:3812-9.
14. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006;12:442-6. (Pubitemid 43166133)
15. Ching CK, Rhodes JM. Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancer. Br J Cancer 1989;59: 949-53. (Pubitemid 19155716)
16. Uehara H, Nakaizumi A, Tatsuta M, Baba M, Takenaka A, Uedo N, et al. Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice: comparison with K-ras mutations. Am J Gastroenterol 1999;94:2513-8. (Pubitemid 29420682)
17. Yokoyama M, Ochi K, Ichimura M, Mizushima T, Shinji T, Koide N, et al. Matrix metalloproteinase-2 in pancreatic juice for diagnosis of pancreatic cancer. Pancreas 2002;24:344-7. (Pubitemid 34441914)
18. Hibi T, Mori T, Fukuma M, Yamazaki K, Hashiguchi A, Yamada T, et al. Synuclein-gamma is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15:2864-71.
19. Yoshida M, Hatano N, Nishiumi S, Irino Y, Izumi Y, Takenawa T, et al. Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography-mass spectrometry. J Gastroenterol 2012;47:9-20.
20. Nishiumi S, Shinohara M, Ikeda A, Yoshie T, Hatano N, Kakuyama S, et al. Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics 2010;6:518-28.
21. Ooi M, Nishiumi S, Yoshie T, Shiomi Y, Kohashi M, Fukunaga K, et al. GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res 2011;60:831-40.
22. Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, et al. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr 2012;26:548-58.
23. Shiomi Y, Nishiumi S, Ooi M, Hatano N, Shinohara M, Yoshie T, et al. GCMS-based metabolomic study in mice with colitis induced by dextran sulfate sodium. Inflamm Bowel Dis 2011;17: 2261-74.
24. Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, Kibi M, Izumi Y, et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One 2012;7:e40459.
25. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009;15:431-40.
26. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 2009;69:4918-25.
27. Fang F, He X, Deng H, Chen Q, Lu J, Spraul M, et al. Discrimination of metabolic profiles of pancreatic cancer from chronic pancreatitis by high-resolution magic angle spinning 1H nuclear magnetic resonance and principal components analysis. Cancer Sci 2007;98:1678-82. (Pubitemid 47487900)
28. Bathe OF, Shaykhutdinov R, Kopciuk K, Weljie AM, McKay A, Sutherland FR, et al. Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev 2011;20: 140-7.
29. Tsugawa H, Bamba T, Shinohara M, Nishiumi S, Yoshida M, Fukusaki E. Practical non-targeted gas chromatography/mass spectrometrybased metabolomics platform for metabolic phenotype analysis. J Biosci Bioeng 2011;112:292-8
30. Tsugawa H, Tsujimoto Y, Arita M, Bamba T, Fukusaki E. GC/MS based metabolomics: development of a data mining system for metabolite identification by using soft independent modeling of class analogy (SIMCA). BMC Bioinformatics 2011;12:131.
31. Urayama S, Zou W, Brooks K, Tolstikov V. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom 2010;24:613-20.
32. Tesiram YA, Lerner M, Stewart C, Njoku C, Brackett DJ. Utility of nuclear magnetic resonance spectroscopy for pancreatic cancer studies. Pancreas 2012;41:474-80.
33. OuYang D, Xu J, Huang H, Chen Z. Metabolomic profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis. Appl Biochem Biotechnol 2011; 165:148-54.
34. Zhang H, Wang Y, Gu X, Zhou J, Yan C. Metabolomic profiling of human plasma in pancreatic cancer using pressurized capillary electrochromatography. Electrophoresis 2011;32:340-7.
35. Jiang JT, Wu CP, Deng HF, Lu MY, Wu J, Zhang HY, et al. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. World J Gastroenterol 2004;10:1675-7. (Pubitemid 38786956)
36. Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007;34:436-43. (Pubitemid 46725785)
37. Takayama R, Nakagawa H, Sawaki A, Mizuno N, Kawai H, Tajika M, et al. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J Gastroenterol 2010;45: 52-9.
38. Yiannakou JY, Newland P, Calder F, Kingsnorth AN, Rhodes JM. Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet 1997;349:389-92. (Pubitemid 27077667)
39. Wingren C, Sandstrom A, Segersvard R, Carlsson A, Andersson R, Lohr M, et al. Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res 2012;72:2481-90.
40. Schrader H, Menge BA, Belyaev O, Uhl W, Schmidt WE, Meier JJ. Amino acid malnutrition in patients with chronic pancreatitis and pancreatic carcinoma. Pancreas 2009;38:416-21.
41. Yamanouchi T, Akanuma Y. Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res Clin Pract 1994;24 Suppl:S261-8.
42. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008;100:1432-8.